milrinone has been researched along with Ventricular Fibrillation in 5 studies
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the pharmocokinetics of intravenous milrinone in patients with severe congestive heart failure during continuous venovenous hemofiltration (CVVH)." | 7.70 | Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ( Matsumoto, H; Okeie, K; Saito, S; Shibata, K; Taniguchi, T, 2000) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 5.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "To evaluate the pharmocokinetics of intravenous milrinone in patients with severe congestive heart failure during continuous venovenous hemofiltration (CVVH)." | 3.70 | Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ( Matsumoto, H; Okeie, K; Saito, S; Shibata, K; Taniguchi, T, 2000) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 1.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "Olprinone was also examined with an intracoronary cotreatment with a PKA inhibitor (H89), a PKC inhibitor (GF109203X), an extracellular signal-regulated kinase kinase (MEK) inhibitor (PD98059), or a p38 MAPK inhibitor (SB203580) throughout the preischemic period." | 1.31 | Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. ( Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J, 2001) |
| "Milrinone infusion was accompanied by a significant QTc interval (QT corrected for heart rate) prolongation." | 1.29 | Comparative cardiac effects of milrinone and sodium nitroprusside in conscious rats. ( Cauchy, MJ; Desjardins, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gurabi, Z | 2 |
| Koncz, I | 2 |
| Patocskai, B | 2 |
| Nesterenko, VV | 1 |
| Antzelevitch, C | 2 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Desjardins, S | 1 |
| Cauchy, MJ | 1 |
| Taniguchi, T | 1 |
| Shibata, K | 1 |
| Saito, S | 1 |
| Matsumoto, H | 1 |
| Okeie, K | 1 |
| Sanada, S | 1 |
| Kitakaze, M | 1 |
| Papst, PJ | 1 |
| Asanuma, H | 1 |
| Node, K | 1 |
| Takashima, S | 1 |
| Asakura, M | 1 |
| Ogita, H | 1 |
| Liao, Y | 1 |
| Sakata, Y | 1 |
| Ogai, A | 1 |
| Fukushima, T | 1 |
| Yamada, J | 1 |
| Shinozaki, Y | 1 |
| Kuzuya, T | 1 |
| Mori, H | 1 |
| Terada, N | 1 |
| Hori, M | 1 |
5 other studies available for milrinone and Ventricular Fibrillation
| Article | Year |
|---|---|
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electr | 2014 |
Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.
Topics: Action Potentials; Animals; Cardiac Electrophysiology; Cardiovascular Agents; Cilostazol; Death, Sud | 2016 |
Comparative cardiac effects of milrinone and sodium nitroprusside in conscious rats.
Topics: Animals; Blood Pressure; Electrocardiography; Heart Rate; Hemodynamics; Male; Milrinone; Myocardial | 1995 |
Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration.
Topics: Adult; Aged; Biological Availability; Female; Heart Failure; Hemodynamics; Hemofiltration; Humans; I | 2000 |
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-D | 2001 |